Dulaglutide Explained: How It Works and Who It's For

Dulaglutide at a glance:

• Drug class: GLP-1 receptor agonist
• Manufacturer: Eli Lilly
• FDA approved: 2014
• Route: subcutaneous injection (single-use pen)
• Typical frequency: once weekly
• Half-life: approximately 5 days
• Cash price (US): $900-$1,000/month without insurance
• Receptor target: GLP-1 receptor

If you're trying to figure out whether Dulaglutide is right for you — or for someone you care about — the right starting point is the basic biology. Dulaglutide is a glp-1 receptor agonist made by Eli Lilly and approved by the FDA in 2014. A1c reductions of 1.0-1.6% and modest weight loss of 2-4 kg in T2D trials. Reduced major adverse cardiovascular events in REWIND.

What is Dulaglutide?

Dulaglutide is a long-acting GLP-1 receptor agonist consisting of two GLP-1 analog molecules linked to an Fc fragment of human IgG4. This structure extends its half-life enough for once-weekly dosing.

Dulaglutide is manufactured by Eli Lilly. Dulaglutide was approved by the FDA in 2014. Its approved indications include type 2 diabetes, cardiovascular risk reduction in T2D. Off-label use happens in clinical practice but is the prescriber's responsibility.

The drug class glp-1 receptor agonist works by acting at the GLP-1 receptor. Here's what to expect.

How Dulaglutide Works in the Body

Dulaglutide is a long-acting GLP-1 receptor agonist consisting of two GLP-1 analog molecules linked to an Fc fragment of human IgG4. This structure extends its half-life enough for once-weekly dosing. The receptor target — GLP-1 receptor — drives the downstream effects users care about: a1c reductions of 1.0-1.6% and modest weight loss of 2-4 kg in t2d trials. reduced major adverse cardiovascular events in rewind.

The pharmacokinetics matter for daily use. Dulaglutide has a half-life of approximately 5 days, which determines how often it is dosed. The standard route of administration is subcutaneous injection (single-use pen), and the typical schedule is once weekly.

For more detail on the underlying biology, see our breakdown of how Dulaglutide works.

Who Uses Dulaglutide?

Dulaglutide is most relevant for people whose situation maps to its approved indications: type 2 diabetes; cardiovascular risk reduction in T2D.

People who should avoid Dulaglutide include those with the following:

• personal or family history of medullary thyroid carcinoma
• MEN 2 syndrome

Common and Serious Side Effects

The most commonly reported side effects of Dulaglutide include:

• nausea
• diarrhea
• abdominal pain
• decreased appetite
• fatigue

Serious risks — uncommon but worth knowing — include:

• pancreatitis
• thyroid C-cell tumors (boxed warning)
• severe hypoglycemia (with sulfonylurea or insulin)

We have a more detailed breakdown in our Dulaglutide side-effects guide.

Dulaglutide vs Alternatives

Common alternatives include semaglutide (Ozempic, also weekly), liraglutide (daily), and tirzepatide (dual agonist with stronger weight effect). If you are weighing Dulaglutide against another option, our comparison pages include Dulaglutide Side Effects Decoded: What's Normal vs. What Isn't, Does Dulaglutide Really Work? An Evidence-Based Results Review, The Real Dulaglutide Price Tag in 2026 — With and Without Insurance.

Bottom Line

Dulaglutide delivers what its label says it delivers. The case for it (or against it) comes down to your specific situation, not abstract comparisons. Multiple randomized controlled trials support its efficacy. If you are considering Dulaglutide, talk to a licensed clinician first — particularly if you take other medications.

Frequently Asked Questions

Related Reading

• Dulaglutide Side Effects Decoded: What's Normal vs. What Isn't
• Does Dulaglutide Really Work? An Evidence-Based Results Review
• The Real Dulaglutide Price Tag in 2026 — With and Without Insurance
• Dulaglutide for Weight Management: How Much Can You Lose?
• Liraglutide Explained: How It Works and Who It's For
• Liraglutide Side Effects: The Complete List and How to Handle Them

Sources

• Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989.
• Marso SP et al. Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes (SUSTAIN-6). NEJM 2016;375:1834.
• Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE). NEJM 2015;373:11.

This page is informational only and is not medical advice. Consult a licensed clinician before starting, stopping, or changing any medication.